Abiomed Inc (ABMD) |
|
347.87 11.57 (3.44%)
|
01-21 01:02 |
|
Open: |
339.12 |
Pre. Close: |
336.3 |
|
High:
|
353.49 |
Low:
|
337.84 |
|
Volume:
|
588,723 |
Market Cap:
|
15,720M |
|
|
|
|
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
354.02 - 355.448 |
355.448 - 356.919 |
|
Low:
|
334.428 - 335.87 |
335.87 - 337.357 |
|
Close:
|
345.459 - 348.012 |
348.012 - 350.643 |
|
Technical analysis |
as of: 2021-01-20 4:43:58 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 412.88  One year: 482.24 |
| Support: |
Support1: 295.43 Support2: 259.54 |
| Resistance: |
Resistance1: 353.49 Resistance2: 412.88 |
| Pivot: |
325.52 |
| Moving Average: |
MA(5): 331.18 MA(20): 320.06
MA(100): 283.33 MA(250): 241.24 |
| MACD: |
MACD(12,26): 13.29 Signal(9): 12.42 |
| Stochastic oscillator: |
%K(14,3): 89.06 %D(3): 81.53 |
| RSI: |
RSI(14): 78.20 |
| 52-week: |
High: 353.49 Low: 119.01 Change(%): 88.6 |
| Average Vol(K): |
3-Month: 29719 10-Days: 35162 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.ABMD has closed above the upper band by 25.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 16.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 19 Jan 2021
Abiomed, Inc. (NASDAQ:ABMD) Given Average Rating of "Hold" by Brokerages - MarketBeat
Thu, 14 Jan 2021
Abiomed Third Quarter Fiscal 2021 Earnings and Conference Call Notification - Yahoo Finance
Tue, 12 Jan 2021
Abiomed To Present At J.P. Morgan Healthcare Conference; Webcast At 5:20 PM ET - Nasdaq
Thu, 07 Jan 2021
Abiomed Continues to Strengthen its Intellectual Property, Now Holds More Than 1000 Patents - Business Wire
Tue, 05 Jan 2021
Is Now An Opportune Moment To Examine Abiomed, Inc. (NASDAQ:ABMD)? - Yahoo Finance
Thu, 31 Dec 2020
Andrew J. Greenfield Sells 5,000 Shares of Abiomed, Inc. (NASDAQ:ABMD) Stock - MarketBeat
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. (M) |
45 |
| Shares Float (M) |
44 |
|
% Held by Insiders
|
2.33 |
|
% Held by Institutions
|
97.47 |
|
Shares Short (K)
|
1,930 |
|
Shares Short P. Month (K)
|
2,050 |
Stock Financials |
|
EPS
|
4.550 |
|
EPS Est This Year
|
2.330 |
|
EPS Est Next Year
|
2.670 |
|
Book Value (p.s.)
|
26.170 |
|
Profit Margin
|
25.88 |
|
Operating Margin
|
28.09 |
|
Return on Assets (ttm)
|
11.5 |
|
Return on Equity (ttm)
|
19.1 |
|
Qtrly Rev. Growth
|
2.3 |
|
Gross Profit (p.s.)
|
15.260 |
|
Sales Per Share
|
17.766 |
|
EBITDA (p.s.)
|
5.488 |
|
Qtrly Earnings Growth
|
376.00 |
|
Operating Cash Flow (M)
|
285 |
|
Levered Free Cash Flow (M)
|
170 |
Stock Valuations |
|
PE Ratio
|
76.45 |
|
PEG Ratio
|
|
|
Price to Book value
|
13.29 |
|
Price to Sales
|
19.58 |
|
Price to Cash Flow
|
55.16 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
